ClinicalTrials.gg
Not yet recruitingNCT07950306RENAL-SHUNTUpdated Nov 20, 2026

Kidney Blood Flow During Open Aortic Surgery (RENAL-SHUNT)

An observational study in Aortic Aneurysm and Suprarenal Cross-clamping, sponsored by University of Bologna. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Bologna · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

During some operations on the abdominal aorta, the surgeon needs to temporarily clamp the aorta above the arteries that supply the kidneys. This can reduce blood flow to the kidneys and may cause acute kidney injury.

This study will follow 50 adults at Policlinico di Sant'Orsola in Bologna, Italy. During their operation, a temporary shunt will perfuse blood from humeral artery to the renal arteries. The treating surgeon decides whether to use the shunt as part of clinical care, independently of study participation.

The researchers will record how often kidney injury occurs in the first 7 days after surgery and how often problems related to the shunt, kidney arteries or arm access occur within 30 days. They will also track the need for dialysis, kidney function and survival over 12 months.

Read the detailed description

RENAL-SHUNT is a single-center prospective observational registry of adults undergoing open abdominal aortic reconstruction requiring suprarenal or supravisceral cross-clamping. The surgical team may select passive renal blood perfusion when it anticipates prolonged or uncertain renal ischemia or considers the patient at high renal risk. The study observes a single exposed cohort. Treatment decisions are made independently of enrollment.

The registry will record baseline kidney function and preoperative acute kidney injury, aortic pathology, urgency, clamp level, periods of renal ischemia and perfusion, hemodynamics, transfusion and complications. Serum creatinine will be collected from routine postoperative assessments where available. Recorded urine output will be used for Kidney Disease: Improving Global Outcomes (KDIGO) classification when available. Follow-up assessments include discharge and postoperative days 30 and 90 and months 6 and 12.

The study targets 50 consecutive participants based on expected accrual over up to 5 years. Event rates will be presented as counts and percentages with 95% confidence intervals. At an observed rate of 20% (10 of 50), the Wilson 95% confidence interval would be approximately 11% to 33%. Changes in serum creatinine and estimated glomerular filtration rate will be summarized from baseline. Subgroup and longitudinal analyses will be exploratory.

The investigators will maintain a screening log and collect data in a coded electronic case report form with a data dictionary and prespecified time windows. Range, consistency and missing-data checks will be completed before database lock. Two investigators will review acute kidney injury stage, major adverse kidney events and serious technique-related events when feasible. Available denominators will be reported for each outcome. The primary outcome will use observed data, with a creatinine-only analysis when urine-output records are incomplete.

02

Conditions studied

  • Aortic Aneurysm
  • Suprarenal Cross-clamping

Browse trials for

Keywords

  • Suprarenal aortic cross-clamping
  • open aortic repair
  • selective renal perfusion
  • Pruitt-Inahara shunt
  • brachial access
03

In context

Aortic Aneurysm

224 studies on the registry are indexed under Aortic Aneurysm; 65 are open to participants now.

This study's planned enrollment of 50 is below the median of 150 across 119 observational studies indexed under Aortic Aneurysm.

Browse Aortic Aneurysm studies →

Lead sponsor

University of Bologna is the lead sponsor of 160 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults undergoing open abdominal aortic reconstruction with suprarenal or supravisceral cross-clamping at Policlinico di Sant'Orsola in Bologna, Italy, for whom the surgical team selects temporary renal blood perfusion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Open abdominal aortic reconstruction requiring suprarenal or supravisceral cross-clamping.
  3. Independent clinical decision by the treating surgeon to use the described renal perfusion circuit.
  4. At least one renal artery intended for shunt perfusion.
  5. Written before surgery through the approved process.

Exclusion criteria

Exclusion Criteria:

  1. Maintenance kidney replacement therapy before surgery.
  2. No initiation of renal shunt perfusion after consent.
  3. Inability or unwillingness to provide under the approved process.
  4. Pregnancy.
  5. Primary renal perfusion using cardiopulmonary bypass or a dedicated visceral perfusion system.
  6. Clinical to brachial access or renal ostial cannulation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Interventions

  • Procedurerenal shunting

    Aortic surgery with suprarenal clamping. Evaluation of renal perfusion with extracorporeal shunt

06

What researchers measure

Primary outcomes

  1. Postoperative acute kidney injury

    Number and percentage of participants meeting KDIGO 2012 criteria. Acute kidney injury is defined by a serum creatinine rise of at least 0.3 mg/dL within 48 hours, serum creatinine at least 1.5 times the reference within 7 days, or urine output below 0.5 mL/kg/hour for at least 6 hours. Reference creatinine is the most recent stable value 7 to 90 days before surgery, or the preoperative value if a stable historical value is unavailable. Cases with preoperative acute kidney injury will be adjudicated and described separately.

    Time frame: End of surgery through postoperative day 7

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Pini R, Lodato M, Abualhin M, Poliseno C, Mattiacci M, Faggioli G. A simplified extracorporeal shunt configuration for temporary selective renal blood perfusion during open aortic surgery. J Vasc Surg Cases Innov Tech. 2026 Aug 31;12(6):102488. doi: 10.1016/j.jvscit.2026.102488. eCollection 2026 Dec. PubMed 42835822 ↗

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 44 observational studies under Aortic Aneurysm, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 107. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2026
First posted
Nov 20, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2031
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950306
Responsible party
Rodolfo Pini (MD, PhD, FEBVS, University of Bologna) — Principal investigator
First posted
Nov 20, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2031 (estimated)
Last update
Nov 20, 2026

Study contacts

Rodolfo Pini, MD, PhD, FEBVS
Contact
rodolfo.pini2@unibo.it
+39-0512143288

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion